Nixxy clears Phase IIb interim
Nixxy Inc. reported interim Phase IIb data showing a 32% response rate vs consensus 28%. Trial enrolled 184 patients.
Key takeaways
- Nixxy Inc. reported interim Phase IIb data showing a 32% response rate.
- The 32% response rate exceeded the consensus estimate of 28%.
- The trial enrolled 184 patients.
Nixxy Inc. reported interim Phase IIb data showing a 32% response rate vs consensus 28%. Trial enrolled 184 patients.